'Optimistic' Pfizer chief won't rule out Astra break-up
Wednesday 14 May 2014
Pfizer chief executive Ian Read is “optimistic” about gaining control of AstraZeneca, but won’t rule out breaking up the British drugmaker if his bid is successful.
“I never use the word hostile,” Read told the London Evening Standard amid expectations that a knock-out offer could be pitched direct to the British firm’s investors.
“We are talking to shareholders, we would like to talk to AstraZeneca… and we are still hopeful of an accommodation,” but meanwhile “we are considering all of our options, of course”.
Read, who today appeared before the Science and Technology Committee before touring City shareholders, said it was important for Viagra-maker Pfizer to win over politicians and the public because: “We want to be welcome in any country we are in. We don’t want to be fighting against society.”
He rejected claims that David Cameron had been cheerleading for his bid: “I believe the government is not supportive of either company, they are supportive of doing science in the UK.”
Read believes AstraZeneca boss Pascal Soriot “had a tough hand dealt” but had created “an interesting pipeline” of drugs.
He said, however: “You don’t transform your pipeline in 15 months. To build a pipeline you need five to six years. I think obviously there are interesting assets in AstraZeneca. I think they are far more interesting if they are combined with our portfolio.”
Read said his own shareholders “understand our position” but of course “they will not reward us if we overpay” for his prey.
US giant Pfizer has until May 26 to bid. Analysts believe the merged company could be carved up along product lines, as Kraft was following its controversial Cadbury takeover.
“I have not said I have got any intention of splitting this company up,” Read said, adding: “If at some point shareholders say to us, we don’t think you are running all of these businesses optimally and we think you could increase value by one of them being sold, well that is a possible option.”
Read told the select committee that Pfizer’s and AstraZeneca’s “science will continue” and that the enlarged group would be a world powerhouse in cancer drugs.
For the second day running, Soriot faced MPs after Read had been grilled by them. He warned that the group’s research work could “quickly lose momentum” because of the distraction of a merger.
- 2 Moscow voted the world's unfriendliest city
- 3 The excuses your boss is most likely to believe when you call in sick
- 4 I'm pansexual – here are the five biggest misconceptions about my sexuality
- 5 More than 11,000 Icelanders offer to house Syrian refugees to help European crisis
The excuses your boss is most likely to believe when you call in sick
Bono's group has made more money from Facebook investment than from all his music
Three-year-old ultra-Orthodox Jewish children told 'the non-Jews' are 'evil' in worksheet produced by London school
Wikipedia rocked by 'rogue editors' blackmail scam targeting small businesses and celebrities
More than 11,000 Icelanders offer to house Syrian refugees to help European crisis
Climate change: 2015 will be the hottest year on record 'by a mile', experts say
Jeremy Corbyn calls Osama bin Laden's killing a 'tragedy' - but was it taken out of context?
If these extraordinarily powerful images of a dead Syrian child washed up on a beach don’t change Europe’s attitude to refugees, what will?
Senior British politicians tell David Cameron: When dead children are being washed up on beaches, it's time to act
If you're not already angry about the refugee crisis, here's a history lesson to remind you why you really should be
Theresa May says migrants should be banned from entering the UK unless they have jobs lined up
iJobs Money & Business
£14000 - £16000 per annum: Recruitment Genius: This company was established in...
£20000 - £25000 per annum + OTE 40k: SThree: SThree are a global FTSE 250 busi...
£20000 - £25000 per annum + competitive: SThree: SThree are a global FTSE 250 ...
Voluntary and unpaid, reasonable expenses reimbursable: Reach Volunteering: St...